A customer in (b)(6) notified biomérieux of obtaining false susceptible fluconazole results for an external quality assessment candida norvengensis strain (biologie prospective 2017-3) when testing with vitek® 2 ast-ys07 test kit (reference 414967).The customer had tested the eqa sample for identification, and candida norvegensis was identified.The customer reported that they had tested a sub-cultured strain of the eqa sample with vitek 2 obtaining mic=8 (s) on initial testing and mic=16 (i) on repeat testing.The minimal inhibitory concentration (mic) value of 8 indicated the fungus to be susceptible to fluconazole; whereas, the expected result was resistant.The medium of culture was chromid candida agar.There is no indication or report from the customer to biomérieux that the discrepant result led to any adverse event related to any patient's state of health.There was no patient associated with this quality strain.A biomérieux internal investigation has been initiated.
|
This report was initially submitted in response to a customer in france notifying biomérieux of obtaining false susceptible fluconazole results for an external quality assessment candida norvengensis strain (biologie prospective 2017-3) when testing with vitek® 2 ast-ys07 test kit (reference 414967).An internal biomérieux investigation was performed that included testing for both fluconazole (flu) and flucytosine (fct) results on vitek® 2 ast-ys07 cards with a strain of candida norvegensis from the biologie prospective survey (mycology 2017- sample 3a).Id testing : identification was confirmed to candida norvegensis on yst card (lot 2430356103) ast testing: · reference method to determine the intended result for fluconazole and flucytosine: broth microdilution, method used to develop the formularies "flu01n" / "fct01n" (in ast-ys07 card).· flu mic = 16 mg/l intermediate · fct mic = 8 mg/l intermediate interpretation according to vitek 2 breakpoints in v7.01 : fda 2009 breakpoints for candida / fluconazole s =8 - i 16-32 - r >/=64.Fda 2012 breakpoints for candida / flucytosine : s =4 - i 8-16 - r >/=32.Note: for antifungals, essential agreement between vitek® 2 card and reference method mics is +/- 2 doubling dilutions.· products & system incriminated: -*ast -ys07 on vitek 2 v7.01 three (3) vitek 2 ast-ys07 card lots were tested from sabouraud dextrose agar (sda).Vitek 2 gave the following results: **flu mic = 16 mg/l i on the three (3) lots tested **fct mic = 4 mg/l s on two (2) lots , 8 mg/l i on the third lot.The vitek 2 results are within essential agreement with the reference mic within +/- 1 doubling dilution.Note: according to fsca 2509 (released april 2015), fct results from ast-ys07 cards (fct01n formulation) should not be reported for any organism.Conclusion: -we duplicated the customer results on ast-ys07 cards (mic flu=16 mg/l i and fct mic=4 mg/l s).-the vitek 2 ast-ys07 cards perform as intended.The vitek 2 values are within essential agreement with the reference results obtained in bmd.-the reference mic for both fluconazole and flucytosine are in the middle of the breakpoints, so the strain can be susceptible or resistant within +/- 2 doubling dilutions.-->borderline strain.
|